Reverse Settlement Bill Clears House Subcommittee With GAO Report Attached
Executive Summary
Legislation that would prohibit brand companies from compensating generic companies to delay entry of their generic drugs cleared the House Subcommittee on Commerce, Trade and Consumer Protection with a caveat: a Government Accountability Office report will keep tabs on whether the act results in earlier or delayed entry of generics to the market
You may also be interested in...
Brand/Generic Settlement Opponents May Have To Settle For Less
If it's Thursday, S. 369 must be on the agenda
Brand/Generic Settlement Opponents May Have To Settle For Less
If it's Thursday, S. 369 must be on the agenda
"Pay For Delay" Legislation Gaining Speed
Provision to limit brand/generic settlements is added to health care reform legislation, but section that would forfeit 180-day exclusivity is not.